Cerus Reports Narrower Quarterly Loss As INTERCEPT Platelet Kits Lift Q4 Sales

Cerus Corp's CERS Q4 FY21 product revenue was $39.9 million, compared to $28.2 million, driven by increased sales of INTERCEPT platelet kits to blood center customers across the U.S.

  • Total revenue increased 49% to $50.1 million, beating the consensus of $44.2 million.
  • Product gross profit was $20.4 million and, for the second consecutive quarter, was the highest in the company's history, increasing by $4.4 million over the prior-year period. 
  • Product gross margin was 51.1% compared to 56.8% for the fourth quarter of 2020 and roughly flat compared to the second and third quarters of 2021.
  • The company said that a decrease in product gross margin was anticipated, as U.S. customers primarily use single-dose platelet kits, which have a lower margin than double dose kits, which the company's international customers more typically use.
  • Cerus posted a EPS loss of $(0.05), lower than $(0.09) a year ago and the consensus of $(0.08).
  • The company held cash and equivalents of $129.4 million as of December 31, 2021.
  • Cerus carried $54.7 million of notes due and a balance on its revolving line of credit of $14.7 million. The company continues to have access to $5 million under its revolving line of credit.
  • Guidance: Cerus reiterated the FY22 product revenue outlook of $157 million - $164 million, representing approximately 20%-25% Y/Y growth.
  • Price Action: CERS shares closed lower by 1.50% at $5.25 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!